
Fresenius SE & Co. KGaA
FSNUF | OTC
$46.86
$0.00 (0.00%)
Nov 2, 2026, 10:10 AM ET · Market open
Company Profile
Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.
Key Executives
| Name | Position |
|---|---|
| Michael Sen | Chief Executive Officer, President & Chairman of Management Board of Fresenius Management SE |
| Pierluigi Antonelli | Member of Management Board of Fresenius Management SE & Chief Executive Officer of Fresenius Kabi |
| Sara Hennicken | Chief Financial Officer & Member of the Management Board - Fresenius Management SE |
| Christian Pawlu | Member of Management Board |
| Michael Sven Moser | Member of the Management Board of Fresenius Management SE |
| Nick Stone | Senior Vice President of Investor Relations & Head of Investor Relations - Fresenius Management SE |
Fresenius SE & Co. KGaA

| Country | Germany |
| IPO Date | Mar 14, 2012 |
| Industry | Medical - Care Facilities |
| Sector | Healthcare |
| Employees | 178,394 |
| CEO | Michael Sen |
Contact Details
Else-Kroener-Strasse 1 Bad Homburg vor der Höhe,
HE 61352 Germany
Stock Details
| Ticker Symbol | FSNUF |
| Exchange | OTC |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000904868 |
| CUSIP Number | n/a |
| ISIN Number | DE000FRE5EN2 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove FSNUF